Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the safety and efficacy of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) in patients with glaucoma or ocular hypertension who have elevated intraocular pressure (IOP) on brimonidine/timolol ophthalmic solution.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Brimonidine Tartrate; Ophthalmic Solutions; Pharmaceutical Solutions; Timolol

Criteria

Inclusion Criteria:

• Glaucoma and/or ocular hypertension in both eyes

• Requires IOP-lowering treatment in both eyes

Exclusion Criteria:

• Other active ocular disease other than glaucoma or ocular hypertension (eg, uveitis, ocular infections or severe dry eye)

• Current or anticipated use of ocular medications other than study medications, except for intermittent use of artificial tears

• Use of oral, injectable or topical corticosteroids within 21 days

• Iridectomy or laser peripheral iridotomy in the study eye within 3 months

• Uncomplicated cataract surgery in the study eye within 6 months

• Incisional glaucoma surgery in the study eye within 12 months